Sunnybrook Research Institute
Toronto, Ontario, Canada
25 recruiting
Showing 1–20 of 35 trials
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Breast Cancer
Pfizer400 enrolled384 locationsNCT07062965
Recruiting
Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
Bristol-Myers Squibb352 enrolled157 locationsNCT07011732
Recruiting
Phase 2Phase 3
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb470 enrolled279 locationsNCT07076121
Recruiting
Phase 3
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer600 enrolled233 locationsNCT06551324
Recruiting
Phase 2Phase 3
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
StrokeAcute StrokeIschemic Stroke
DiaMedica Therapeutics Inc728 enrolled66 locationsNCT05065216
Recruiting
Phase 3
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Endometrial Cancer
Karyopharm Therapeutics Inc276 enrolled217 locationsNCT05611931
Recruiting
Phase 1
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
MelanomaNon-small Cell Lung CancerThyroid Cancer+10 more
Pfizer124 enrolled77 locationsNCT05538130
Recruiting
Phase 3
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Urinary Incontinence, Stress
Eli Lilly and Company1,000 enrolled136 locationsNCT07202884
Recruiting
Phase 3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,080 enrolled260 locationsNCT07213804
Recruiting
Phase 3
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Non-small Cell Lung CancerAdvanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.480 enrolled56 locationsNCT07185997
Recruiting
Phase 3
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Non-small Cell Lung CancerBrain Tumor
InSightec30 enrolled10 locationsNCT05317858
Recruiting
Phase 2
Fisetin in Mild Alzheimer's Disease
Alzheimer DiseaseAlzheimer DementiaAlzheimer Dementia (AD)+4 more
Sunnybrook Health Sciences Centre5 enrolled1 locationNCT07279714
Recruiting
Phase 3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer400 enrolled382 locationsNCT05253651
Recruiting
Phase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled120 locationsNCT06982521
Recruiting
Phase 3
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
Peripheral Arterial DiseaseInflammationAtherosclerosis of Extremities
Population Health Research Institute6,150 enrolled70 locationsNCT04774159
Recruiting
Phase 1Phase 2
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Advanced Solid Tumor
Eikon Therapeutics156 enrolled53 locationsNCT06253130
Recruiting
Simulation for Operating Room Ergonomics
Occupational Injuries
Sunnybrook Health Sciences Centre28 enrolled1 locationNCT05541354
Recruiting
Phase 1
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
ALS (Amyotrophic Lateral Sclerosis)
Eli Lilly and Company32 enrolled12 locationsNCT07100119
Recruiting
Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Breast Cancer
Pfizer1,020 enrolled518 locationsNCT06760637
Recruiting
Phase 1Phase 2
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
Amyotrophic Lateral Sclerosis(ALS)Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Regeneron Pharmaceuticals42 enrolled16 locationsNCT06351592